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Background: Signal transduction mediated by protein kinases and phosphatases is complex 
and highly coordinated. The mitogen activated protein kinases (MAPKs) are key components 
that transduce extracellular stimuli to biological responses by a three-tier module. The 
biological functions of steroid receptor coactivator-3 (SRC-3), a coactivator of nuclear 
hormone receptors and numerous transcription factors, is regulated by multiple pathways 
involving the MAP kinase signaling cascades. The oncogenic SRC-3 protein is found to be 
overexpressed in multiple human cancers, such as breast, prostate and lung cancer, and is 
implicated in the regulation of multiple physiological and pathological functions. The 
upstream kinase of SRC-3 phosphorylation at S857 in vivo has yet to be found, although 
ERK3 has been reported to phosphorylate this site.         
Aim: In this study, we investigate the association of the ERK3-MK5 pathway with SRC-3 
phosphorylation at S857 residue in the human lung cancer cells H1299. 
Methods: In vitro and in vivo kinase assays, immunoprecipitation assays and western blot 
analysis. 
Results: Unlike the MAPK kinases p38, ERK2 and ERK3, the MAPKAP kinases MK2 and 
MK5 phosphorylate SRC-3 at S857 efficiently in vitro. siRNA mediated knockdown of ERK3 
and MK5 demonstrates no such effect in vivo. Blocking of the p38 MAPK pathway resulted 
in decreased levels of SRC-3 S857 phosphorylation compared to control, whereas stimulation 
with the stress-activator anisomycin significantly raised the phosphorylation levels in vivo.    
Conclusion: In contrast to the study of Long et al, our results demonstrate the p38 MAPK 
pathway, rather than the ERK3-MK5 pathway, to be involved in the phosphorylation of SRC-
3 at S857. Our observations should be further investigated to verify this association and to test 
if the phosphorylation is mediated through the MAPKAP kinase MK2.         
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1 INTRODUCTION 
 
Living cells monitor and respond to both their external and internal environment through 
signal transduction - a vital process carried out by complex and highly coordinated networks 
of proteins, which react to environmental changes. Binding of an impermeable signal 
molecule (ligand) to a receptor localized on the plasma membrane recognizing this specific 
ligand can result in the activation of an inherent enzymatic activity of the receptor, and thus 
stimulate one or more intracellular transducing proteins. The modulation of the protein(s) can 
eventually lead to the activation or inhibition of so called “effector proteins” involved in 
fundamental cellular processes such as apoptosis, differentiation, division, growth, 
metabolism, motility and transcription. Activity modulations of effector proteins can be 
effectuated by covalent modifications at the molecular level. Protein phosphorylation and de-
phosphorylation, carried out by protein kinases and phosphatases respectively, are among the 
most common and important modifications (1, 2).    
 
1.1 Protein kinases 
 
Five hundred and eighteen protein kinase genes have been identified in the human genome 
(2). The protein kinases are enzymes that mediate most of the signal transduction in 
eukaryotic cells by modifying the substrate activity of other downstream proteins through 
covalently attaching phosphate to the side chain of serine, threonine or tyrosine. Thus, the 
protein kinases are divided into subgroups based on their catalytic specificity as tyrosine- or 
serine/threonine kinases. Some kinases have dual specificity and can phosphorylate both 
tyrosine and serine/threonine (3). The serine/threonine-specific kinases constitute 
approximately 80% of the protein kinases.   
The balance of reversible protein phosphorylation is tightly regulated in order to maintain 
homeostasis, and also plays a critical role in intracellular processes during development, 
physiological responses and in functioning of the nervous and immune systems. Irregular 
phosphorylation results in, or is itself an outcome of, major diseases such as cancer, diabetes 
and rheumatoid arthritis (2, 4).Due to the role of protein kinases in a wide range of biological 
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processes mentioned above, they are attractive drug targets for the development of selective 
inhibitors, or possibly activators (2).     
1.1.1 Tyrosine kinases 
The tyrosine kinases (TKs) can be divided into two main groups: receptor TKs (RTKs) and 
non-receptor TKs. Non-RTKs are cytoplasmic proteins responsible for the transduction of 
extracellular signaling to downstream proteins, while the RTKs are membrane spanning cell 
surface receptors with a ligand-binding domain in the extracellular region, a single 
transmembrane helix, and a cytoplasmic region that contains the protein tyrosine kinase 
domain, in addition to carboxy terminal and juxtamembrane regulatory region. Upon ligand-
binding, the RTKs will dimerize and autophosphorylate by catalyzing the transfer of the γ 
phosphate of ATP to hydroxyl groups of tyrosine groups on the receptors themselves and on 
target proteins. This is important for the transduction of extracellular signaling to the 
cytoplasm (5-7).  
Through the phosphorylation of protein serine/threonine kinases, the RTKs activate various 
intracellular signaling pathways, including the phosphatiodylinositol-3 kinase/Akt (PI3K/Akt) 
pathway and the Raf-MEK-MAPK pathway (8). The latter pathway is of great interest and is 
widely investigated at many laboratories worldwide. This pathway is activated by RTKs 
binding to growth factors, such as epidermal growth factor (EGF), which lead to sequentially 
activation of the cascade Shc-Grb2-SOS-Ras-Raf-MEK-MAPK (9, 10).       
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1.1.2 Mitogen-activated protein kinases (MAPKs) 
Fourteen genes in the human genome have been identified to code for mitogen-activated 
protein kinases. These kinases, expressed in all cell types, define 7 distinct signaling pathways 
(Figure 1) (11). The MAPKs regulate specific cellular responses to stimuli such as cytokines, 
growth factors, antigens, toxins and stress (temperature change, irradiation, and changes in 
cell shape, cell-cell interaction and extracellular matrix). The cellular responses differ from 
cell type to cell type (12).  
 
Figure 1: The MAPK signaling cascade of conventional and atypical MAPKs. The dotted lines indicate that the 
connection between the respective kinases remains to be fully elucidated. Figure is modified from Kostenko et al, 2012 (13). 
 
The MAPKs are important intermediates in signal transduction pathways and are initiated by 
various cell surface receptors. They carry out signal transduction through a three-tier module - 
a cascade of phosphorylation at serine/threonine residues of the protein kinases. The MAPKs 
are activated by dual-specificity MAPK kinases (MAPKKs/MAP2Ks) by phosphorylation of 
both the threonine and tyrosine residues of a conserved T-X-Y motif within the activation 
loop of the MAP kinase. MAP2Ks are themselves phosphorylated and activated by MAPK 
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kinase kinases (MAPKKKs/MAP3Ks). The signals of the MAPK cascades can be amplifying 
by one successive protein in the cascade being more abundant than its regulator. 
 (12, 14, 15).  
The MAPKs are evolutionary conserved and mainly phosphorylate serine and threonine 
residues which are next to proline rich residues. The docking domains of target substrates 
determine the specificity of the MAP kinases. By tethering the specific substrate to their 
docking motifs, the MAPKs help in the efficiency of the interactions. The phosphorylation 
reactions are regulated by various transcription factors (TFs) and enzymes, and further control 
of the interactions are mediated by other binding partners, subcellular localizations, 
conformational changes and protein stability (16).    
The MAPKs are divided into two groups; the conventional kinases consisting of 
ERK1/ERK2, ERK5, JNKs and p38, and the atypical kinases comprising ERK3/ERK4,  
ERK7and NLK (11). The structural relationship of the conventional and atypical MAPKs is 
illustrated in Figure 2. 
 
 
Figure 2: Schematic illustration of the structure of human MAPKs. Kinase domains (blue) with phosphorylation sites are 
shown along with nuclear localization sequence (NLS) and transactivation domain (TAD). C34: Conserved region in 
ERK3/4. AHQr: Ala/His/Gln-rich domain. Figure is adapted from Coulombe et al, 2007 (11).     
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1.1.2.1 Conventional kinases 
ERK1/ERK2 
Extracellular signal-regulated kinase 1 and 2 (ERK1/2, 43 and 41 kDa respectively) share 
83% amino acid identity (17).  These MAPKs are expressed to various extents in all tissues, 
and are activated upon phosphorylation within the conserved Thr-Glu-Tyr (TEY) motif in 
their activation loop by the dual specificity kinases MEK1/2 (18). MEK1/2 is activated by the 
kinase Raf, which is itself activated by Ras. Ras is activated by SOS (son of sevenless), which 
stimulates Ras to change GDP to GTP, allowing subsequent interaction with Raf. This 
cascade is often referred to as the Ras – Raf – MEK- ERK pathway and is among the most 
extensively studied pathway (19). The cascade is initiated by stimuli such as growth factors, 
cytokines, carcinogens and virus infections. Ligands for heterotrimeric guanine nucleotide-
binding protein (G-protein) –coupled receptors and transforming agents are also activators of 
this pathway (20). When ERK1/2 is activated, significant amounts of the kinases accumulates 
in the nucleus where they activate nuclear substrates like the TFs SRC-1, Elk-1, c-Fos, c-Myc 
and STAT3. In addition, ERK1/2 phosphorylates substrates in other cellular compartments, 
e.g. membrane proteins (CD120a and calnexin) and cytoskeletal proteins (neurofilaments and 
paxillin). Several other substrates are activated by ERK1/2 as well; p90 ribosomal S6 kinase 
(RSK), mitogen and stress-activated kinase (MSK) and MAPK-interacting kinase (MNK) (18, 
21).        
ERK5 
ERK5 (MAPK7) is ubiquitously expressed, but is especially found to be overexpressed in the 
heart, skeletal muscles, placenta, lungs and kidneys. The pathway of this conventional ERK 
plays an important role in embryogenesis, the development of the cardiovascular system and 
tumor neovascularization (22). It is activated by stress stimuli, cytokines, hormones, growth 
factors and neurotransmitters.  It is phosphorylated by MEK5 on the residues Thr218 and 
Tyr220 within its conserved Thr-Glu-Tyr (TYE) motif in the activation loop (similar to 
ERK1/2). This kinase is also called BMK1 (Big MAPK1) due to a larger molecular mass than 
other ERKs due to a C-terminus extension, which regulates activation, autophosphorylation, 
subcellular localization and nuclear shuttling. Upon activation and autophosphorylation, 
ERK5 translocate to the nucleus where it phosphorylates and activates various TFs such as 
MEF2, Sap1, c-FOS and c-myc (16, 23).  
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JNKs 
The c-Jun NH2-terminal kinase (JNK) family of MAPKs is encoded by three genes; Jnk1 and 
2 which are ubiquitously expressed, and Jnk3 whose expression is limited to the brain, heart 
and testis. Alternative splicing generates 10 distinct JNK isoforms which are involved in 
proliferation, apoptosis, motility, metabolism and DNA-repair. Together with p38, the JNKs 
constitute the stress-activated protein kinases (SAPKs). 
Cytokines and environmental stress, such as UV radiation, growth factor deprivation, toxins 
and DNA-damaging agents, trigger the activation of MAP3Ks which phosphorylates and 
activates the two MAP2K isoforms MEK4 and MEK7. These two kinases will in turn 
phosphorylate and activate JNKs by dual phosphorylation of tyrosine and threonine residues 
at distinctive TPY motif. When JNKs are activated, they translocate from the cytoplasm to the 
nucleus where they phosphorylate distinct transcription factors, for example c-Jun which is a 
member of the activator protein-1 (AP-1) transcription factors (24-26).        
p38 
As mentioned above, p38 is a SAPK. p38 has four isoforms; α, β, γ (also called ERK6) and δ, 
which of p38α is the most well characterized (24). This group of MAPKs was discovered 
during a screen of drugs inhibiting TNF-α mediated inflammatory response (27). The p38 
MAPK is characterized by the conserved Thr-Gly-Tyr (TGY) motif in its activation loop, 
which is phosphorylated by MEK3 and MEK6. MEK3 and MEK6 are activated by various 
MAP3Ks that are themselves activated by low molecular weight GTP-binding proteins from 
the Rho subfamily (e.g. Rac1, Cd242, Rho and Rit). The p38 pathway is induced by physical 
and chemical stresses, such as oxidative stress, hypoxia, x-ray and UV radiation and 
cytokines. In some instances, p38 is found to be activated by MEK4 (an activator of JNKs). 
Upon activation, p38 translocate from the cytosol to the nucleus where it phosphorylates 
Ser/Thr residues on its many substrates, amongst which MK2 is of great interest. The p38 
pathway plays a role in the regulation of apoptosis, cell cycle progression, growth, 
differentiation, in the activation of p53 and may also be implicated in invasion and metastasis 
by its regulation of MMP2 and MMP9 (24, 28, 29).    
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1.1.2.2 Atypical kinases 
ERK3/4 
ERK3 and ERK4 are atypical MAP kinases with 44 % sequence homology to ERK1 and 
ERK2.There is major factors contributing to the distinction of the classical/conventional and 
atypical ERKs. First, ERK3 and ERK4 have a unique C-terminal extension which contributes 
to their larger size compared to ERK1 and ERK2. Second, ERK3 and ERK4 have a different 
motif in the activation loop compared to the conventional MAPKs; the canonical Thr-Xaa-Tyr 
(TXY) motif is replaced by a Ser-Glu-Gly (SEG) motif (Figure 2)  (30).  
ERK3 is found in both the nucleus and the cytoplasm, while ERK4 is mainly localized in the 
nucleus. Unlike ERK4, ERK3 is highly unstable with short half-life due to rapid degradation 
by ubiquitination via the 26S proteasome pathway (31, 32). MK5 is a downstream target of 
ERK3 and the phosphorylation of the key regulatory site Thr182 of MK5 by ERK3 leads to 
nuclear export of both the kinases. Increased levels of MK5 subsequently increases the 
activity of ERK3 by MK5 acting as a chaperone for ERK3 (15).    
ERK7 
ERK7 was first identified and characterized by Abe et al in 1999 (33). They reported that 
albeit ERK7 has the TEY motif, it is constitutive active, and that its c-terminal domain is 
required, rather than kinase activity, for its cellular localization and function as a negative 
regulator of growth. Very little information is obtained about its biological functions and its 
up- and downstream proteins since then. However, ERK7 has been shown to be a specific 
regulator of degradation of estrogen receptor alpha (ERα) through the 26S proteasome 
pathway in human breast cells (in which ERK7 is highly expressed). Loss of ERK7 has 
demonstrated to correlate with the progression of breast cancer (34).         
NLK  
Nemo-like kinase (NLK), a Ser/Thr kinase, is classified as an atypical kinase because of its N- 
and C-terminal extensions that are not present in the conventional MAPKs and because it has 
only a single residue in its activation loop which can be phosphorylated. NLK is activated by 
the Wnt pathway and by various cytokines (e.g. IL-6 and TGF-β), and it can regulate the Wnt 
pathway both positively and negatively (35).    
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1.1.3 MAPK-activated protein kinases (MAPKAPKs) 
The MAPKAPK family has eleven family members that are generally activated by mitogens 
through the ERK1/2 kinase cascade (RSK1-4 and MNK2), stress stimuli through the p38 
kinase cascade (MK2-3 and possibly MK5), or both of these cascades (MSK1-2 and MNK1) 
(see Figure 1) (18). Based on the homology of the kinase catalytic domain, the MAPKAPKs 
are considered to belong to the calcium/calmodulin-dependent protein kinase (CaMK) 
superfamily (36). 
The RSKs and MSKs possess two distinct and functional kinase domains; the N-terminal 
kinase domain (NTKD) and the C-terminal kinase domain (CTKD). The MNKs, MK2-3 and 
MK5 have a single kinase domain homologous to the CTDK of the RSKs and MSKs. The 
activation loop sequences is similar in all of the MAPKAPKs and, as mentioned, is 
phosphorylated by either ERK1/2 or p38 MAP kinases. The RSKs are mainly involved in the 
regulation of gene expression, and its substrates for phosphorylation is, amongst others, Fos 
and cyclic-AMP-responsive-element binding protein (CREB). The MSKs are known to 
regulate gene expression by phosphorylating histone H3 (18, 36).  
1.1.3.1 MAPK-activated protein kinase 2 (MK2) 
MK2 is located in the nucleus and exist in an inactive, preformed complex with p38α that 
translocate to the cytoplasm upon activation. This translocation is initiated when p38 is 
activated by an upstream kinase (e.g. MEK3/6). MK2 is activated by p38 phosphorylating its 
three residues T221, S272 and T334. Maximal activation is obtained by the phosphorylation 
of any two of the sites, whereas phosphorylation of any one residue is in insufficient for its 
activation. Upon T334 phosphorylation, a nuclear export sequence (NES) of MK2 is 
unmasked and the complex of MK2-phospho p38 translocate from the nucleus to the cytosol. 
The NLS and NES are located in distinct regions of the C-terminus of MK2 and MK3, 
whereas these two signals are overlapping in MK5 (4, 36).  
MK2 is found to regulate lipopolysaccharide (LPS-) induced up-regulation of several cytokine 
mRNAs, e.g. those encoding tumor necrosis factor and interleukin 6 and 8. The small heat 
shock protein Hsp27 is also phosphorylated by MK2, which modifies the ability of Hsp27 to 
act as a chaperone and thereby stabilize actin filament and regulate the cytoskeletal 
architecture. Finally, MK2 is also involved in the cell-cycle control at the CDC25- and p53-
dependent checkpoints (31, 36).    
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1.1.3.2 MAPK-activated protein kinase 5 (MK5) 
MK5 was originally identified as a p38-regulated/activated protein kinase (hence it is also 
called PRAK). Since then, it has been discovered not to be a direct downstream target of p38 
and it does not act as a chaperone for p38 in vivo (31, 32). This kinase has two isoform that 
differs in two amino acids in MK5’s unique C-terminal extension (36). The activation of MK5 
is reported to be dependent on both ERK3 and ERK4, and these two MAP kinases are found 
to be physiological regulators of MK5 activity (31).   
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1.2 Protein kinase A (PKA) 
 
The protein kinase A (PKA) is a tetramer consisting of a dimeric regulatory subunit (R2) and 
two monomeric catalytic subunits (C2), and has at least two isoforms. The type I isoform is 
mainly found in the cytoplasm, and the type II isoform is primarily associated with 
membranes, subcellular organelles and the cytoskeleton. The PKA pathway is stimulated by 
ligands binding to a G protein-coupled receptor (GPCR), which leads to increased cAMP 
levels. When cAMP bind to the R subunit of PKA, the catalytic subunits dissociates and 
become active. The free catalytic can then phosphorylate Ser and Thr residues which enables 
entrance into the nucleus and allow further phosphorylation of TFs, such as CREB, NF-κB 
and nuclear receptors. PKA modifies and influences the outcome of receptor activation by 
cross-talk with other pathways and is especially important in cellular differentiation and 
proliferation (37).           
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1.3 Steroid receptor coactivator-3  
 
The p160 steroid receptor co-activator (SRC) family is a co-activator group consisting of 
three members: SRC-1/Nuclear receptor coactivator-1 (NCOA1), SRC-2/NCOA2/ 
TIF2/GRIP1 and SRC-3. SRC-3 was discovered in 1997 and is also known as Amplified In 
Breast cancer 1 (AIB1), NCOA3, Receptor Associated Coactivator-3 (RAC3), and p300/CBP 
interacting protein (CIP) (38).  
The SRC-3 gene is localized in the chromosomal region 20q12 and the SRC-3 protein is a 
relatively large protein with its 160 kDa (39). Figure 3 illustrates the structural domains of 
SRC-3 of which three are considered to be basic structural domains analogues to the other 
SRC family members. First is the N-terminal basic helix-loop-helix-Per/ARNT/Sim domain 
(bHLH-PAS), which is the most highly conserved domain and is necessary for the 
interactions of SRC-3 with other DNA-binding proteins. Second is the receptor-interaction 
domain (RID) with its three LXXL motifs (L= leucine, X= any amino acid) by which SRC-3 
binds to the ligand-activated nuclear receptors. Third is the C-terminal domain containing two 
intrinsic transcriptional activation domains; AD1 and AD2. AD1 interacts with histone 
aetyltransferases, and AD1 interacts with methyltransferases (39, 40).   
 
Figure 3: Structural domains of SRC-3 and its interacting partners. Illustration (not to scale) of conserved functional 
domains of SRC-3including bHLH/PAS (basic helix-loop-helix/per/ARNT/Sim homologous domain), S/T (serine/threonine) 
rich domain, a nuclear receptor interacting domain (RID) where L=LXXLL, the CBP/p300 interaction domain (CID), a 
polyglutamate region (Q), and a histoneacetyltransferase (HAT) domain. AD: activation domain. ER: estrogen receptor. AR: 
androgen receptor. PR: progesterone receptor. GR: glucocorticoid receptor. TR: thyroid receptor. aPKC: atypical protein 
kinase C. FAK: focal adhesion kinase. Figure is modified from York and O’Malley, 2010 (40).         
 
The SRC-3 protein mediates transcriptional activities of nuclear hormone receptors (NRs) 
such as thyroid receptors, estrogen receptors (ER) and progesterone receptors (PR). The NRs 
are ligand-dependent transcription factors (TFs) which translocate to the nucleus when bound 
to its ligand. The ligand-NR complex recognizes specific DNA sequences and activates gene 
transcription after binding to its response elements upstream of target genes. The 
  12 
transcriptional activation is optimized by interaction of hormone-activated NRs with co-
activator proteins. This leads to an assembly and stabilization of a pre-initiation complex that 
conducts target gene transcription (38, 41).   
SRC-3 also potentiates activities of several TFs, such as AP-1, E2F-1, nuclear factor κB (NF-
κB), PEA3, and Signal Transducer and Activator of Transcription (STAT) (38). When the 
TFs binds to SRC-3, other chromatin modification factors, such as acetyltransferases (CBP 
and p300) and methyltransferases (CARM1 and PRMT1), are recruited. This results in 
modification of chromatin structure and activation of transcription of their target genes. 
Changes in concentration or activity of SRC-3 may result in altered expression level of many 
genes, and thereby influence a variety of cellular processes (42). The association of some of 
the interaction partners of SRC-3 and their tumor promoting properties are illustrated below.   
 
 
Figure 4: SRC-3 is implicated in multiple signaling pathways. SRC-3 promotes multiple hallmarks of cancer by its ability 
to coactivate various nuclear receptors and transcription factors. Direct interactions are illustrated by solid lines, whereas the 
dotted lines indicate indirect interaction. Figure is modified from Tien and Xu, 2012 (38). 
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2 AIM OF THESIS 
 
A recent study by Long et al has shown that SRC-3 is a substrate of the atypical MAP-kinase 
ERK3 (43).  They report the phosphorylation of SRC-3 by ERK3 to be specific for the residue 
Ser-857 (S857), and this phosphorylation was discovered to be important for the induction of 
MMP2, 9 and 10 expression, and thereby metastasis of lung cancer cells. The pharmacology 
research group of Tromsø has repeated some of these experiments, but with different 
outcome: SRC-3 appear to be a greater substrate of MK5 in vitro, rather than of ERK3. Like 
ERK3, MK5 is found to regulate expression of MMP2, 9 and 10. The research group has also 
found MK5 to be a downstream target and effector of ERK3, and the activation of MK5 to be 
associated with its phosphorylation at Thr-182 by ERK3 (32).  
Considering this information, we wish to further investigate SRC-3 as a downstream target for 
the ERK3-MK5 pathway in the human lung cancer cells H1299 by addressing the following 
questions: 
- Does ERK3 phosphorylate SRC-3 at S857 in vitro and/or in vivo? 
- Does MK5 phosphorylate SRC-3 at S857 in vitro and/or in vivo? 
- Does co-transfected ERK3 and SRC-3 bind in vivo, and how will the phosphorylation 
of SRC-3 at S857 be influenced by co-transfection of ERK3 and SRC-3?  
- How will siRNA-mediated knockdown of MK5 and ERK3 influence phosphorylation 
of SRC-3 at S857?    
- If the ERK3-MK5 pathway is not involved in the phosphorylation of SRC-3 at S857 in 








Plasmid Catalog # Source 
pCMV Tag2B SRC-3  
R:1.9  
780ng/µl 28.10.13 
 Kindly provided by professor 




Recombinant proteins Catalog # Source 
Active-ERK2  
Division of Signal 
Transduction Therapy (DSTT), 





 Pharmacology research group, 
University of Tromsø 
MEK inhibitor PD 184.352 Catalog # ALX-270-471 
Alexis Biochemicals 
p38 inhibitor SB-202190 
Catalog #  
BML-EI294-0001 
PKA inhibitor H-89 
 Kindly provided by professor 




20 nmole  
Catalog # 16706 
 
Ambion® 
Scrambled SiRNA MK5 
Negative Control siRNA #1 
40 nmole 
Catalog # AM46 
SiRNA ERK3 
MAPK6  
Silencer® validated siRNA 
20 nmole 
Catalog # AM553133 
Anisomycin  Sigma-Alderich®, St. Louis, 
MO, U.S.A. EGF  
 
Plasmid purification kits 
QIAGEN® Plasmid Plus Midi Kit Catalog # 12945 QIAGEN®, Gmbh Hilden, Germany 
 
Bacterial strains 
E. Coli, DH5α competent cells Pharmacology research group, University of Tromsø 
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Growth culture for bacteria 
Ampicillin 
Sodium salt 
Catalog # A9518 Sigma-Alderich®, St. Louis, MO, U.S.A. 
LB-broth 
 
10 g/l Bacto™ tryptone, Difco 
5 g/l Bacto™ yeast extract, Difco 
5 g/l NaCl 
pH adjusted to 7.4 
SUMP section, University hospital in 




10 g/l Bacto™ tryptone, Difco 
5 g/l Bacto™ yeast extract, Difco 
5 g/l NaCl  
pH adjusted to 7.4 
10 g/l agar 
Ampicillin Sodium Salt, Sigma-
Alderich® 
S.O.C. medium 
20 g/l Bacto™ tryptone, Difco 
5 g/l Bacto™ yeast extract, Difco 
8.6 mM NaCl 
2.5 mM KCL 
10 mM MgCl 
10 mM MgSO4 
20 mM Glucose 




Carcinomic human non-small 
cell cancer, lung 
LGG standards ATCC® Number: CRL-5803™
 
 
Cell culturing medium 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Catalog # D5796 
Sigma-Alderich®, St. Louis, 
MO, U.S.A. 
 
Cell transfection kits 
Lipofectamine® 2000 Transfection 
Reagent 
Catalog # 11668-019 Invitrogen, Life 
Technologies™, Carlsbad, 
CA, U.S.A. 
Lipofectamine® LTX  
with Plus Reagent 
Catalog # 15338-100 
 
  
  16 
Buffers, solutions and chemical reagents  
Method  Composition/Catalog # Source 
Cell culturing 
Dulbecco’s Phosphate 
Buffered Saline (PBS) 
 
Catalog # D8537 
 Sigma-Alderich®, 




Catalog # T4049 
Penicillin-Streptomycin 
(10000 U/ml – 10 mg/ml) 
Catalog # P0781 
Fetal Bovine Serum 
(FBS) Superior 




Opti-MEM® I Reduced 
Serum Medium 








  17 
Buffers, solutions and chemical reagents (continued) 
Method  Composition/Catalog # Source 
Cell lysis & IP  SRC-3 lysis buffer 
 
50 mM Tris [pH 7.5] 
150 mM NaCl 
0.5% Igepal 
10 mM NaF 
1 mM EDTA 
1 mM EGTA 
1 mM sodium orthovandate 
10 mM β-glycerophosphate 
5 mM NaPPi  
Milli-Q water ad 100 ml 
(1 tablet Complete, Mini, 
Protease inhibitor cocktail 
per 10 ml lysis buffer) 
Pharmacology 
research group, 
University of Tromsø 
HA-lysis buffer 50 mM Tris [pH 7.5] 
150 mM NaCl 
2 mM EDTA 
1 mM EGTA 
1% Triton X-100 
5 mM NaPPi 
50 mM NaF 
1 mM VO4
2- 
10 mM β-glycerophosphate 
Milli-Q water ad 100 ml 
(1 tablet Complete, Mini, 
Protease inhibitor cocktail 
per 10 ml lysis buffer) 
MKK lysis buffer 
 
20 mM Tris [pH 7.5] 
1% TritonX-100 
5 mM NaPPi 





0,27 M sucrose 
10 mM β-glycerophosphate 
Milli-Q water ad 100 ml 
 RIPA lysis buffer 50 mM Tris [pH 7.5] 
150 mM NaCl 
1% Sodium deoxycholate 
1% Igepal 
0.02% SDS 
5 mM NaPPi 
50 mM NaF 
1 mM VO4
2- 
10 mM β-glycerophosphate 
Milli-Q water ad 100 ml 
(1 tablet Complete, Mini, 
Protease inhibitor cocktail 
per 10 ml lysis buffer) 
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Buffers, solutions and chemical reagents (continued) 
Method  Composition/Catalog # Source 
Cell lysis & IP  
Complete, Mini,  
Protease inhibitor cocktail 
tablets 







Catalog # M8823 
Sigma-Alderich®, 
St. Louis, MO, 
U.S.A. 
PureProteome™ Protein 
G Magnetic Bead System  






29 g Tris base 
144 g glycerin 
1 L methanol 







TBS buffer 10x 
200 ml Tris 1M [pH 7.5] 
400 g NaCl 
10 g KCl 





TBS-T buffer 1x 
200 ml Tris 1M [pH 7.5] 
400 g NaCl 
10 g KCl 





 NuPAGE® LDS Sample 
Buffer (4X) 
Catalog # NP0008  
NuPAGE® Sample 
Reducing Agent (10X) 
Catalog # NP0009 
NuPAGE® MES SDS 
Running Buffer (20X) 
Catalog # NP0002-02 
NuPAGE® Novex®  
4-12 % Bis-Tris Protein 
Gels 1.0mm   
Catalog # NP0321BOX 
SeeBlue® Plus2 
Pre-Stained Standard   
Catalog # LC5925 
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Buffers, solutions and chemical reagents (continued) 












Catalog # P/N 927-40000 
Tween® 20  Catalog # P1379 
Sigma-Alderich®, 




50 mM Tris-HCL 
0,1 mM EGTA 
1 mM sodium vandate 
1 mM DTT 






3 % (v/v) 10 mM ATP 
5 % (v/v) 1 M MgCl2 
92 % Assay buffer 
Kinase buffer (2 x) 
100 mM Tris 
0,2 mM EGTA 
20 mM Magnesium acetate 
200 µM ATP 
Milli-Q water ad 10 ml 
Dilution buffer 
50 mM Tris 
1mg/ml BSA 
Milli-Q water ad 1 ml 
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Antibodies  
Primary antibodies Source Secondary antibodies Source 
SRC-3 (NCOA-3)  





Anti p-S857 SRC-3 
(1:2000) 
Custom made, Division of 
Signal Transduction 
Therapy (DSTT), 
University of Dundee, UK 
Anti-Sheep IgG (H&L) 
Donkey IRDye 800CW 







Rabbit polyclonal IgG  
200 µg/ml 
Catalog # sc-459 
GST-antibody (1:200-1000) 
Santa Cruz Biotechnology, 
Inc. Santa Cruz, CA, 
U.S.A. 
Donkey anti-Rabbit 
IRDye® 680 LT 
0,5 mg 







Rabbit polyclonal IgG  
200 µg/ml 
Catalog # sc-9119 
Anti SRC-3(1:1000) 
Santa Cruz Biotechnology, 
Inc. Santa Cruz, CA, 
U.S.A. 
ERK 2 (C-14) 
Rabbit polyclonal IgG 
200 µg/ml 
Catalog # sc-154 
Anti ERK2 (1:1000) 
Santa Cruz Biotechnology, 
Inc. Santa Cruz, CA, 
U.S.A. 
Pan-Actin Antibody 
Catalog # 4968 
Anti actin (1:1000) 
Cell signaling Technology, 
Inc.Danvers, MA 
U.S.A. 
Anti-FLAG® M2 Antibody 
Murine monoclonal IgG,  
200 µg, 2 mg/ml 
Catalog # 200470-21 
Anti Flag M2 (1:1000)  
Stratagene® 











(T202/Y204) (E10)  
Mouse mAb pERK2 
Catalog # 9106S 
Anti P-ERK1/2 (1:2000) 





Anti myc (1:200) 
ATCC® 
Number:CRL-1729 ™  
PRAK (A-7) 
Mouse monoclonal IgG1 
Catalog # sc-46667 
Anti MK5 A7 (1:500) 
Santa Cruz Biotechnology, 




0,05 mg, 0,45 mg/ml 
Catalog # H00005597-M02 
Anti ERK3 (1:500) 
Abnova,  
Neihu District, 
Taipei City, Taiwan 
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4 METHODS 
 
4.1 Construction of expression vectors 
 
4.1.1 MidiPrep 
QIAGEN® Plasmid Plus Midi Kit was used according to protocols from the manufacturer for 
the purification of plasmids. The concentrations were measured in ng/µl by using the software 
NanoDrop 1000 V3.8 and the instrument NanoDrop® ND-1000 spectrophotometer (Thermo 
Fisher Scientific, Wilmington, U.S.A.). 
4.2 Mammalian cell culture techniques 
 
4.2.1 Cell culture 
The H1299 cells were cultured in DMEM supplemented with 10 % FBS and 1 % antibiotics 
(10000 U/ml penicillin and 10 mg/ml streptomycin). The cell cultures were grown in Thermo-
scientific nunc® Easy Flasks™, and incubated in HERAcell® 150i CO2 incubator with 
following conditions: 37 °C, 5 % CO2 and 80-95 % relative humidity.  
4.2.2 Harvesting cells and cell splitting 
The PBS media (stored at room temperature) and Trypsin (stored at – 20 °C, once opened: 2-4 
°C) was pre-warmed to 37 °C. Media covering the monolayer of cells in the T-flask was 
discarded. In order to have optimal effect of Trypsin, the bottom of the T-flask was washed 
quickly with 0.2 ml PBS/cm
2
 surface. To dethatch the cells from the surface, 40 µl 
Trypsin/cm
2
 was added and the flask rocked gently to make sure that the entire monolayer 
was covered. The T-flask was incubated at 37 °C for 2-5 minutes and checked under 
microscope to confirm that all the cells were floating and if there were any lumps of cells. 
Appropriate amount of medium was added to dilute and neutralize Trypsin. When the cells 
were not counted and seeded for transfection, they were split 2-4 times a week according to 
confluence and planned assays.           
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4.2.3 Counting cells 
A Bürker Counting Chamber was used for counting of the cells. The chamber was cleaned 
with water and ethanol, and the coverslip was moisturized by water in order to fix it on the 
counting chamber. The cell suspension was mixed gently by pipetting up and down 8 times to 
ensure that cell lumps was dispersed to form a homogenous cell suspension. 500 µl cell 
suspension was pipetted to an Eppendorf tube. From this, 20 µl was pipetted to the counting 
chamber under the cover slip to be drawn into place by capillary forces. The counting 
chamber was placed under the microscope, and as many A windows in the chamber needed to 
reach 200 cells was counted. The viable cell concentration per ml was calculated using the 
following formula: 
                        
                  
                              
4.2.4 Seeding cells 
The amount of cell suspension needed per well was calculated: 
                              
                            
                    
The calculated volume of cell suspension was pipetted to a centrifuge tube and growth 
medium was added to form a master suspension. The amount growth medium added was 
calculated according to number and type of wells used:  media used for a 6 well plate was 
calculated from the total volume of 2 ml per well of cell suspension and media, and the total 
volume for a 60 mm well was 3 ml. The master suspension was plated into the wells and 
placed in the incubator overnight. 
4.2.5 Transfection with Lipofectamine® 2000 
Cells seeded 24 hours before (or when the confluence was 70-80 %) were used for 
transfection. A master mix of Lipofectamine® 2000 and Opti-MEM® was prepared (3 µl 
Lipofectamine® 2000 and 247 µl Opti-MEM® per sample) and incubated at room 
temperature for at least 5 minutes. 250 µl Opti-MEM® was pipetted in each autoclaved 
Eppendorf tubes (one tube per sample). Depending on the planned assay, appropriate amount 
of plasmid was pipetted into the tubes. 250 µl master mix was added to the tubes and 
incubated for 20 minutes at room temperature. In the meantime, the media from the wells was 
discarded and 500 µl Opti-MEM® was added to each well before incubating at 37 °C again. 
After 20 minutes, all the contents in each Eppendorf tube were pipetted to the wells and then 
  23 
incubated at 37 °C. After 4-6 hours, 4 ml growth medium was pipetted to each well when 
using 60 mm wells or 2 ml when using a 6 plate well.  
4.2.6 Harvesting cells after transfection (cell lysis) 
Growth medium was removed 24-48 hours post transfection, and a washing step with 2 ml 
PBS was carried out twice. After discarding PBS, 300 µl of lysis buffer (with phosphatase and 
protease inhibitors) appropriate for the planned assay was distributed evenly in each well. 
After 1 min, the cells were collected using a rubber cell scraper and the cell lysates was 
transferred to autoclaved Eppendorf tubes. The lysates were sonicated briefly (for 2 seconds) 
and incubated on ice for 20 minutes. After centrifuging the lysates at 13 000 rpm for 15 min. 
at 4 °C, the supernatant was carefully pipetted to autoclaved Eppendorf tubes while ensuring 
not to transfer debris to the new tubes. The cell lysates were stored at -70 °C when not used 
the same day. 
4.3 Immunoprecipitation 
 
Cell lysates stored at -70°C were thawed on ice. Magnetic beads (10 µl per sample; 5 µl when 
using magnetic beads pre-coated with antibodies) were washed 3 times with 500 µl ice-cold 
lysis buffer with phosphatase inhibitor (type of lysis buffer used varied according to planned 
assays). The beads were re-suspended in ice-cold lysis buffer with phosphatase and protease 
inhibitors. When using magnetic beads without antibodies, the cell lysates were added 10 µl 
antibodies and incubated on a rotator wheel at 4 °C for 60 min. This step was skipped when 
magnetic beads pre-coated with antibodies were used. 10 µl washed magnetic beads (5 µl 
when pre-coated with antibodies) were added to each sample and incubated on a rotator wheel 
at 4 °C for 1 hour (3 hours when pre-coated). The mix of lysate and magnetic beads was 
washed first 3 times with 500 µl ice-cold lysis buffer with phosphatase inhibitor, and then 2 
times with 500 µl 50 mM Tris [pH 7.5]. Proteins were eluted with 40 µl sample reducing 
buffer (1.4 x) per sample and incubated at 70 °C for 10 min. The samples were cooled and 
stored at -70 °C when not used for SDS-PAGE and WB the same day.  
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4.4 Western blot 
 
4.4.1 SDS-PAGE  
39 µl cell lysate was added 15 µl LDS Sample Buffer (4x) and 6 µl Sample Reducing Agent 
(10x). The samples were incubated at 70 °C for 10 min. 40 ml NuPAGE® MES SDS Running 
Buffer (20x) was diluted with 800 ml dH2O. The manufacturer’s protocol was followed to 
prepare further for sample loading. 15-20 µl of each sample and 5 µl SeeBlue® Plus2 Pre-
Stained Standard was loaded into the wells of the SDS-PAGE gel. When Magic Marker® was 
used, it was loaded 1 µl of it. The electrophoresis was run at 200 V for 45 minutes when 
analyzing CID-fragments of SRC-3, and for 1 hour and 30 minutes when analyzing full-
length SRC-3.  
4.4.2 Blotting 
Prior to blotting a nitrocellulose membrane was washed for a minimum of 5 minutes in 
blotting buffer, and 4 filter papers and 5-6 blotting pads were soaked in blotting buffer. A 
blotting unit was prepared by layering these components to a sandwich as illustrated in the 
figure below: 
 
Figure 5: Illustration of the blotting unit. 
The blotting unit was placed in an XCell Sure Lock™ Mini-cell. The inner chamber was 
filled with blotting buffer, and the outer chamber was filled with fresh, cold deionized water. 
The blot was performed by the NuPage blot program at 30 V (160 mA) for 2 hours for full-
length SRC-3 (1 hour 30 minutes for CID-SRC-3). After the blotting, the membrane was 
washed for 1 hour with 25 ml blocking buffer on a Gyro-Rocker. The membrane was then 
transferred to a 50 ml centrifuge tube containing 5 ml blocking buffer, 5 µl Tween 20 and 
primary antibodies in dilutions as described in section 3. The tube was incubated overnight on 
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a rotator at slow speed at 4 °C. Next day, the membrane was washed 3 x 5 minutes with 
washing buffer by placing the beaker on the Gyro-Rocker. The secondary antibody was 
diluted (1:10 000) in 5 ml washing buffer in a 50 ml centrifuge tube covered with aluminum 
foil in order to protect the antibodies against light. The membrane was transferred to this tube 
and incubated on a rotator at slow speed for 1 hour at room temperature. The membrane was 
washed 2 x 5 minutes with washing buffer. The protein bands were detected by using the 
ODYSSEY® Sa Infrared Imaging System. 
 
4.5 In vitro kinase assay 
 
The kinase solutions were prepared by mixing kinase buffer, GST-SRC-3CID, Milli-Q water 
and appropriate amount of kinase analyzed (Appendix 1) Eppendorf tubes containing the 
kinase assay mix were incubated at 30 °C for specific time intervals (Appendix 1). The kinase 
reaction was stopped by adding LDS Sample Buffer and Sample Reducing Agent, and then 
incubated at 70 °C for 10 minutes prior to WB analysis. To confirm phosphorylation of S857 
at CID WT, anti P-S857 SRC-3 antibody (1:2000) was used.  
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5 RESULTS 
 
In contrast to the results published by Long et al do results from our group, using a 
radioactive in vitro kinase assay, indicate that ERK3 does not phosphorylate SRC-3 very 
efficiently (Tømte, Almahi and Seternes, unpublished results). Closer inspection of the 
sequences around the Serine 857 of the SRC-3 (RAVSL) reveals that this serine is not within 
an optimal sequence for phosphorylation by MAP kinases (S/T-P). The sequence around S857 
of SRC-3 resembles more an optimal motif for phosphorylation by protein kinase A (PKA) or 
MAPKAP kinases (R-X-X-S/T). This site can be phosphorylated by PKA and IKK in vitro 
(44). As we know that MAPKAPK5 is a direct downstream effector of ERK3, we could 
observe that MK5, rather than ERK3, could phosphorylate SRC-3 in vitro. In order to 
investigate if this was true also in vivo, we needed to generate a phospho-specific antibody 
against this site. A phosphospecific antisera against S857 of SRC-3 was developed in 
collaboration with the Division of Signal transduction therapy (DSTT) at the University of 
Dundee. In order to use this antibody on western blots using cell extract, we had to verify that 
the antibody could recognize SRC-3 phosphorylated on S857. In addition, we needed to 
optimize the western blot protocol. 
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5.1 Optimizing and validating anti-phospho-SRC-3 antibody 
5.1.1 Dilutions of anti-phospho-SRC-3 antibody 
The antibody anti P-S857 SRC-3 (2
nd
 bleed, sheep) is designed to specifically recognize 
phosphorylated S857 at the SRC-3 protein or its fragments. This assay was performed to 
confirm that the antibody recognized SRC-3 phosphorylated on S857 and to find the optimal 
concentration of this antibody when used as a primary antibody for WB analysis. We tested 
the dilutions 1:500, 1:1000 and 1:2000. Glutathione S-transferase (GST) served as a control 
while testing the GST-SRC-3 fragment fusion proteins of wildtype: GST-SRC-3CID WT 
(hereafter CID WT), and a mutant of the CID domain where the phospho-acceptor site Serine 
857 is changed to an unphosphorylatable alanine: GST-SRC-3CID S857A (hereafter CID 
S857A), with and without MK5. In Figure 6, we can see that CID WT incubated with MK5 is 
phosphorylated to a significantly greater extent compared to CID WT alone or CID S857A 
incubated with MK5. The blot with anti P-S857 SRC-3 dilution 1:2000 (Figure 6C) shows 
greater specificity towards S857 phosphorylation and gives clearer bands. This dilution will 
be used for further western blot analysis.  
 
Figure 6: Optimizing anti P-S847 SRC-3 antibody for use as a primary antibody for WB analysis. WB analysis of cell 
extracts of cell transfections with GST, CID WT, CID WT co-transfected with MK5 and CID S857A co-transfected with 
MK5. Anti P-S857 SRC-3 antibody used as primary antibody with various dilutions; 1:500 (A), 1:1000 (B) and 1:2000 (C). 
The membrane C was incubated a second time with GST-antibody 1:200 (D). 
 
A second incubation of this membrane with GST-antibody was conducted in order to confirm 
equal loading to each lane (Figure 6D). The minor differences in band intensity do not explain 
the differences seen in the phosphorylation of S857. In other words, the results from co-
incubation of CID WT and MK5 are not a consequence of extensive loading of cell extract in 
this lane.   
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5.1.2 Dilutions of CID WT co-incubated with MK5 analyzed with anti P-S857 SRC-3 
antibody  
We wanted to test if the detection of the phosphorylated SRC-3 was linear using different 
dilutions of phosphorylated GST-SRC-3 and anti-phospho-SRC-3 as primary antibody.  
Concentrations 1:1000 (Figure 7 A) and 1:2000 (Figure 7B/C) of the antibody were tested. 
This experiment confirmed our results from the previous test of the anti-phospho-SRC-3 
antibody that showed the 1:2000 dilutions to be more specific and give clearer bands 
compared to 1:1000 dilutions. We can see in Figure 7 that the phosphorylation of S857 at CID 
WT by MK5 is increasing with increasing concentrations (from right lanes to left side). This 
verifies the anti-phospho-SRC-3 antibody to be very specific. Quantitative analysis of band 
intensity implies the phosphorylation of S857 at CID WT by MK5 to be linear, but more 
parallels are needed to statistically confirm this correlation.  To control for amount of GST-
SRC-3 loaded to each well, the second membrane (1:2000 anti P-S857 SRC-3) was incubated 
with GST-antibody (Figure 7C). As wished, the band intensities are decreasing with 
increasing dilutions.  
 
 
Figure 7: Analysis of different dilutions of CID WT co-expressed with MK5 using anti P-S857 SRC-3 as primary 
antibody. Cell extract of CID WT and MK5 was diluted with 2 x LDS buffer. The dilutions and quantitative values are 
specified at the bottom of each lane. The anti P-S857 SRC-3 antibody was diluted 1:1000 (A) and 1:2000 (B). Membrane in 
B was further incubated with GST-antibody1:200 (C). 
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5.2 In vitro kinase assays with SRC-3 CID as substrate 
 
Same conditions were kept for the in vitro kinase assays in order to be able to compare the 
results. It was investigated whether the distinct kinases were upstream of SRC-3 CID and had 
SRC-3 CID as their substrate. The kinases we studied were MK5, MK2, ERK2, ERK3 and 
p38. 
5.2.1 In vitro kinase assay with CID and MK5 
WB analysis of concentrations of 5, 10, 20 and 40 ng MK5 was assessed after the kinase 
reaction had been incubated for 15 minutes (left panel Figure 8), and 100 ng MK5 reaction 
proceeded for 5, 10, 15 and 30 minutes (right panel Figure 8). Figure 8 shows protein bands 
of membranes incubated with anti P-S857 SRC-3 antibody (A) and GST-antibody (B). The 
band intensity for row A left panel is increasing proportionally (Appendix 2), which indicates 
linear phosphorylation of CID by MK5. The phosphorylation is not linear for 100 ng MK5 at 
different time intervals as seen in row A right panel (Appendix 3). This can be explained by 
the phosphorylation process happening too fast at concentration of 100 ng MK5, and the 
process is outside linearity already before 5 min. The purpose of incubation with GST-
antibody is to check for equal loading, as described earlier, and in this assay we want to 
analyze the amount of CID in the lanes in the right and left panel. Corresponding amounts of 
CID was added to the kinase reactions in the left panel, and the amount of CID is the same in 
all lanes of the right panel since 20 µl solutions were taken out at different time intervals from 
the same kinase reaction. This is reflected by the results seen in row B in the right panel, and 



















































Figure 8: WB analysis of in vitro kinase assay with CID and MK5. Left panel: Kinase reaction containing 5, 10, 
20 and 40 ng MK5 and CID incubated for 15 min. Right panel: Kinase reaction containing 100 ng MK5 and CID 
incubated for 5, 10, 15 and 30 min. Membrane incubated with anti P-S857-SRC-3 antibody 1:2000 (A) and GST-
antibody 1:200 (B).   
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5.2.2 In vitro kinase assay with CID and MK2 
This kinase assay was conducted with the same conditions as the previous kinase assay. The 
MK2 solution had a 60 fold higher concentration calculated in U/mg compared to MK5, and 
was therefore diluted by a factor of 60 in order to compare the results with MK5. To facilitate 
comparison of MK2 and MK5, the results for MK2 are shown in the same concentration 
labels (ng/µl) as MK5 since the concentration is corresponding in U/mg. The left panel results 
for MK2 (Figure 9) corresponds to left panel results of MK5 (Figure 8, Appendix 4), but in 
Figure 9 right panel we can see different outcome even though same amounts of kinases and 
CID were mixed for the kinase reactions. One explanation for these results is the possibility of 
CID degradation before adding it to the reaction. The Eppendorf tube with CID had been 
thawed on ice and then frozen before thawed a second time when used for the 100 ng MK2 
reaction. This  is reflected in Figure 9 row B as the amount of CID added to 100 ng MK2 
reactions are same in each lane (right panel) and all the bands have much lower intensity 
compared to left panel (CID from distinct Eppendorf tubes). Low amounts of CID gives less 
phosphorylation (row A, right panel) despite high concentration (100 ng) of MK2, which 


















































15 min 100 ng 
Figure 9: WB analysis of in vitro kinase assay with CID and MK2. Left panel: Kinase reaction 
containing CID and 5, 10, 20 and 40 ng MK2 respectively, incubated for 15 min. Right panel: Kinase 
reaction containing CID and 100 ng MK2 incubated for 5, 10, 15 and 30 min. Membrane incubated with 
anti P-S857 SRC-3 antibody 1:2000 (A) and GST-antibody 1:200 (B). 
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5.2.3 In vitro kinase assay with CID and ERK2 and ERK3  
ERK3 phosphorylates CID-SRC-3 at S857 to greater extent than ERK2 (Figure 10). The 
phosphorylation is not proportionally increasing.  
 
 
Figure 10: WB analysis of in vitro kinase assay with CID + ERK2 and CID + ERK3. Upper panel: Kinase reaction 
containing ERK2 equivalent to 100 ng MK5 and CID incubated for 15, 30 and 60 min (left), and likewise kinase reaction of 
ERK3 (right) is represented. Primary antibody: Anti P-S857 SRC-3 (1:2000). Lower panel: Blot in upper panel was further 
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5.2.4 In vitro kinase assay with CID and ERK3 or p38 
Compared to ERK3, p38 does not phosphorylate CID SRC-3 at S857 efficiently, but the 
phosphorylation is increasing with time.   
 
Figure 11: WB analysis of in vitro kinase assay with CID + p38 and CID + ERK3. Upper panel: Kinase reaction 
containing p38 equivalent to 100 ng MK5 and CID incubated for 15, 30 and 60 min (left) and 50, 100, 200 and 300 ng ERK3 
incubated with CID for 15 min. Primary antibody: Anti P-S857 SRC-3 (1:2000). Lower panel: Blot in upper panel was 
further incubated with GST-antibody (1:200). The arrows indicate GST-p38 and GST-CID-SRC-3 phosphorylation. 
SeeBlue® was used for band identification. 
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5.2.5 In vitro kinase assay – comparison of MK2, MK5, ERK2, ERK3 and p38 
In Figure 12 we can see that equal amounts of MK2 and MK5 phosphorylate S857 at CID-
SRC-3 to a significantly greater extent compared to ERK2, ERK3 and p38, which has similar 
effect on S857 phosphorylation.     
 
Figure 12: WB analysis of in vitro kinase assay with CID + MK2, MK5, ERK2, ERK3 and p38. Upper panel: Kinase 
reaction containing CID and MK2, MK5, ERK2, ERK3 and p38 of equal amounts (equal to the kinase activity of 100 ng 
MK5) incubated for 15 min. Primary antibody: Anti P-S857 SRC-3 (1:2000). Lower panel: Blot in upper panel was further 
incubated with GST-antibody (1:200). The arrows indicate GST-MK2, GST-p38 and GST-CID-SRC-3 phosphorylation. 
SeeBlue® was used for band identification. 
  
  34 
5.3 Immunoprecipitation method for full length SRC-3 
 
The IP method, followed by WB analysis, was optimized by altering parameters such as type 
of lysis buffer, sonication versus vortex mixing (cell lysis step), and type of magnetic beads 
and antibodies, in addition to their incubation-time (data not shown). The most efficacious 
method tested for IP, from transfection to WB analysis, and materials used are described 
below. 
- Transfection method: Lipofectamine® 2000.  The cells were harvested after 24 hours. 
- Method for harvesting cells after transfection (with sonication for 2 seconds); see 
section 4.2.6.  Lysis buffer: HA –lysis buffer with phosphatase and protease inhibitors. 
- 5 µl of Anti-FLAG® M2 Magnetic Beads washed with HA-lysis buffer with 
phosphatase inhibitors was added to each lysate and incubated at 4 °C for 3 hours.  
The IP method described in section 4.3 was followed.  
- SDS-PAGE was conducted as described in section 4.4.1. 20 µl of each lysate was used 
and the analysis was run for 45 minutes at 200 V and 120 mA.  
- The WB program was run for 2 hours at 30 V and 160 mA. 
The results are presented in Figure 13 for analysis of both IP lysates and whole cell extracts 
(WCEs), and shows that Myc-ERK3 does not increase the levels of Flag-SRC-3 
phosphorylation. 
 
Figure 13: Myc-ERK3 does not increase levels of Flag-SRC-3 phosphorylation. 500 000 H1299 cells per 60 mm wells 
were transfected with either 1000 ng Flag-SRC-3, 1000 ng Myc-ERK3 or 1000 ng of both plasmids. Non-transfected cells 
serve as control. Cells were lysed with HA-lysis buffer and Flag-SRC-3 was immunoprecipitated (incubation with 5 µl Anti-
FLAG® M2 Magnetic Beads for 3 h). IP lysates and WCEs were analyzed by SDS-PAGE and WB. Anti P-S857 SRC-3 
(1:2000) was used to determine the levels of SRC-3 phosphorylated at S857, and anti myc for the detection of ERK3 levels. 
The assay was repeated and the results are representative for both parallels.   
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5.4 In vivo kinase inhibitor assays with endogenous SRC-3  
 
It was investigated whether distinct kinases could be upstream of endogenous SRC-3 in vivo 
by using WB analysis of IP lysates and WCEs of various transfected kinases inhibitors.   
5.4.1 In vivo kinase assay with MEK-inhibitor and p38-inhibitor  
This assay with H1299 cells treated with MEK-inhibitor and p38 inhibitor was carried out to 
test if inhibition of endogenous MEK or p38 altered the phosphorylation of the S857 residue 
of endogenous SRC-3. The results are shown in Figure 14 where we can see more than 85 % 
decrease of SRC-3 phosphorylation (Appendix 6) when p38 is inhibited. In comparison, 
MEK-inhibition does not decrease the phosphorylation of SRC-3 (the phosphorylation is in 
fact increased by 76 % by MEK-inhibition). The phosphorylation of ERK2, which is 
downstream of MEK, is significantly reduced as expected. However, the effect of p38-
inhibition on ERK2 phosphorylation was not expected.   
 
 
Figure 14: The p38-inhibitor decrease the levels of endogenous SRC-3 phosphorylated at S857 in vivo. 500 000 H1299 
cells per 60 mm wells were stimulated for 2 h with 10 µM of either DMSO (control), MEK-inhibitor or p38-inhibitor. Cells 
were lysed with MKK lysis buffer and endogenous SRC-3 was immunoprecipitated (PureProteome™ Protein G Magnetic 
Beads incubated with 20 µl SRC-3 antibody for 1 h). IP lysates and WCEs were analyzed by SDS-PAGE and WB. Anti P-
S857 SRC-3 (1:1000) was used to determine the levels of endogenous SRC-3 phosphorylated at S857. Staining with anti P-
ERK2 (1:2000) and anti ERK2 (1:1000) confirm successful inhibition of MEK and p38. Quantitative values are specified at 
the bottom of each lane of P-S857 SRC-3. The assay was repeated and the results are representative for both parallels. 
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5.4.2 In vivo assay with Anisomycin 
This assay was carried out to investigate how an increase of p38 by stimulation with 
anisomycin would affect the phosphorylation of endogenous SRC-3 at S857. The results are 
presented in Figure 15, which shows a raise in levels of phosphorylated S857 SRC-3 as well 
as levels of phosphorylated p38 compared to the control.  
 
 
Figure 15: Anisomycin-induced increase in p38 increases the phosphorylation of SRC-3 at S-857 in vivo. 500 000 
H1299 cells per 60 mm wells were stimulated for 30 min with 25 µg/ml Anisomycin. Untreated cells serve as control. Cells 
were lysed with MKK lysis buffer and endogenous SRC-3 was immunoprecipitated (PureProteome™ Protein G Magnetic 
Beads incubated with 20 µl SRC-3 antibody for 1 h). IP lysates and WCEs were analyzed by SDS-PAGE and WB. Anti P-
S857 SRC-3 (1:1000) was used to determine the levels of endogenous SRC-3 phosphorylated at S857. Staining with anti 
SRC-3 (1:2000) was used to determine the levels of total SRC-3, and anti P-p38 (1:1000) to check the levels of p38. 
Quantitative values are specified at the bottom of each lane of P-S857 SRC-3. The assay was repeated and the results are 
representative for both parallels. 
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5.4.3 In vivo assay with the PKA-inhibitor H-89 
Figure 16 shows the results of an in vivo assay with the PKA-inhibitor H-89. Inhibition of 
PKA does not alter the level of endogenous SRC-3 phosphorylation at S857.   
 
 
Figure 16: The PKA-inhibitor H-89 does not affect the levels of endogenous SRC-3 phosphorylated at S857 in vivo. 
500 000 H1299 cells per 60 mm wells were stimulated for 2 h with 10 µM of the PKA-inhibitor H-89. Cells were lysed with 
MKK lysis buffer and endogenous SRC-3 was immunoprecipitated (PureProteome™ Protein G Magnetic Beads incubated 
with 20 µl SRC-3 antibody for 1 h). IP lysates were analyzed by SDS-PAGE and WB. Anti P-S857 SRC-3 (1:1000) was used 
to determine the levels of endogenous SRC-3 phosphorylated at S857. Staining with anti SRC-3 (1:1000) shows total amount 
of SRC-3. Quantitative values are specified at the bottom of each lane for P-S857 SRC-3. 
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5.5 siRNA knockdown of MK5 and ERK3  
 
siRNA mediated knockdown of MK5 and ERK3 was assessed, and the results shows minimal 
effect on the phosphorylation of SRC-3 (at least there is no decrease of phosphorylation) as 
shown in Figure 17. 
 
Figure 17: siRNA mediated knockdown of ERK3 does not affect phosphorylation of endogenous SRC-3 at S857. 
500 000 H1299 cells per 60 mm wells were transfected with 20 nM of either control (scrambled) siRNA, siRNA MK5 or 
siRNA ERK3. Cells were lysed with MKK lysis buffer after 48 h and endogenous SRC-3 was immunoprecipitated 
(PureProteome™ Protein G Magnetic Beads incubated with 20 µl SRC-3 antibody for 1 h). IP lysates and WCEs were 
analyzed by SDS-PAGE and WB. Anti P-S857 SRC-3 (1:1000) was used to determine the levels of endogenous SRC-3 
phosphorylated at S857. Staining with Anti MK5 A7 (1:500) and anti ERK3 (1:500) confirms knockdown of MK5 and 
ERK3, respectively. Staining with anti-aktin (1:1000) was used as control for loading. Quantitative values are specified at the 
bottom of each lane of P-S857 SRC-3. The assay was repeated and the results are representative for both parallels. 
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6 DISCUSSION 
 
SRC-3 plays an important role in various cellular processes and is implicated in inflammation, 
angiogenesis, proliferation, chemo resistance, tumor growth, invasion and metastasis. This 
oncogenic nuclear receptor coactivator is reported to be overexpressed in multiple human 
cancers, e.g. breast, lung and prostate cancer. SRC-3 is a coactivator for nuclear hormone 
receptors and numerous transcription factors. This property enables it to control multiple 
growth pathways simultaneously, and it holds future promise for clinical cancer therapy (38, 
45, 46).  
Several research groups are studying SRC-3 worldwide; some are focusing on elucidating up- 
and downstream targets of SRC-3, while others are studying possible inhibitors. The SRCs 
are large proteins which previously were not considered to be “druggable” targets. However, 
the great efforts have paid off as a result of the recent discovery of two small-molecule 
inhibitors (SMIs) of SRC-1 and SRC-3; Gossypol and Bufalin (47, 48). If Bufalin, or future, 
SMIs of SRCs succeed to enter clinical trials, and hopefully manage to reach the clinic as 
anti-cancer therapeutics, it will be beneficial for various groups of cancer patients. Gossypol 
(also called Ascenta Therapeutics -101) is currently in clinical trials for the treatment of 
prostate and lung cancer, and leukemia. It is noteworthy that better understanding of up- and 
downstream targets of SRCs will be advantageous in optimizing cancer therapy when 
considering the possibility to inhibit protein kinases, phosphatases or other signaling 
molecules, which could potentially be up regulated as a consequence of SRC inhibition, with 
combinatorial therapeutics.  
Long et al (43) have reported that ERK3 phosphorylate SRC-3 at the S857 residue, but our 
findings do not support the theory that ERK3 is an upstream regulator of SRC-3 
phosphorylation at S857. The results of our in vitro and in vivo assays indicate the p38 MAPK 
pathway, rather than the ERK3 pathway, to be involved in the phosphorylation of SRC-3 at 
S857.  
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Optimizing and validating anti-phospho-SRC-3 antibody    
A highly specific antibody for the SRC-3 phosphorylation of S857 was a prerequisite for this 
study in order to obtain reliable results. The optimized dilution of the custom-made antibody 
anti-P3857 SRC-3 was determined to be 1:2000. The antibody was validated and ascertained 
to be very specific as it did not bind to the mutant of the CID (CID S857A). Additional 
analysis of various dilutions of CID WT co-incubated with MK5 (section 5.1.2) further 
strengthened our presumptions of this antibody’s specificity and the notion of 1:2000 dilution 
being the optimized dilution. Dilutions of 1:1000 were used when analyzing IP lysates due to 
low amounts of endogenous SRC-3 in the cells.     
 
MK5 phosphorylates SRC-3 at S857 in vitro, but not in vivo 
The results of the in vitro assay of MK5 demonstrates linear phosphorylation at 
concentrations between 5-40 ng for kinase reactions incubated for 15 minutes, but not for 100 
ng MK5 reactions incubated for 5-30 minutes. siRNA mediated knockdown of MK5 resulted 
in no change in the levels of phosphorylated S857 residues of endogenous SRC-3 in vivo 
when compared to the control (Appendix 6). Thus, MK5 does not appear to be a direct 
upstream kinase for SRC-3 in living cells.  
 
ERK3 phosphorylates SRC-3 at S857 in vitro, but not in vivo 
In vitro assays show that ERK3 phosphorylates the S857 residue of SRC-3 more efficiently 
than ERK2. We also repeated the immunoprecipitation assay described in the study of Long et 
al by first optimizing an IP method for full length SRC-3, and then analyzing IP of Flag- 
SRC-3 co-transfected with Myc-ERK3. Myc-ERK3 was found to not increase the levels of 
Flag-SRC-3 phosphorylation at S857 in vivo. The observations of siRNA mediated 
knockdown analysis of ERK3 in vivo are also consistent with these findings. The in vivo 
assays were repeated with corresponding results. Based on our results so far, we wanted to 
investigate other MAPKs or MAKPAKPs to be upstream kinases of SRC-3.     
 
  
  41 
ERK2 phosphorylates SRC-3 at S857 in vitro  
Our data from in vitro assays indicated that ERK2, like ERK3 and p38, phosphorylates SRC-3 
at S857 with little efficiency. By using MEK-inhibitor (which inhibits the basal activity of the 
MAPKAP kinases MSKs, MNKs and RSKs), we also demonstrate that ERK1/2 cannot be the 
upstream kinases of SRC-3 in vivo. Based on these results, we find the MAPKAPKs RSKs 
and MNK2 (which are downstream targets of ERK1/2) not to be directly involved in SRC-3 
phosphorylation at S857. We also tested the in vivo effect of PKA on the phosphorylation of 
S857 by using the PKA-inhibitor H-89. Compared to the control, the results show no effect on 
the phosphorylation of endogenous SRC-3 at S857. H-89 inhibits MSK1 with equal potency 
as PKA, and inhibits the RSKs as well (49). This suggests that the MAPKAP kinases RSKs 
and MSK1 are not involved in the SRC-3 phosphorylation at S857. Wu et al have reported 
PKA to phosphorylate S857 of SRC-3 in HEK293 cells in contrast to our study, which were 
carried out by using H1299 lung cancer cells. The H1299 cells have K-Ras mutations and are 
p53 null, which could interfere with normal cross-talk between the different signaling 
pathways. This might explain the interesting effect seen on ERK2 phosphorylation, which 
notably decreases upon p38-inhibition.                    
 
p38 does not phosphorylate SRC-3 at S857 in vitro, but is involved in vivo  
In vitro assays of p38 did not show direct phosphorylation of SRC-3 S857. Conversely, MK2 
demonstrated linear phosphorylation at concentrations between 5-40 ng for kinase reactions 
incubated for 15 minutes, and also for 100 ng MK5 reactions incubated for 5-30 minutes in 
vitro. MK2 is a direct downstream target of the p38 pathway, and based on our data, we 
wanted to investigate if this pathway could be upstream of SRC-3 in vivo.    
The results from our in vivo assays where p38 was inhibited showed decreased SRC-3 
phosphorylation at S857. Conversely, stimulation of p38 with the stress-activator anisomycin 
increased the phosphorylation more than 2-fold. This demonstrates that p38 could be a 
possible indirect upstream kinase of SRC-3 phosphorylation of S857 (through MK2). The in 
vivo assays were repeated with corresponding results, but more parallels are needed to 
statistically confirm our results. However, we have demonstrated that of the MAPKs, p38 is 
the most likely MAP kinase to be the upstream of SRC-3 phosphorylation at S857 in H1299 
cells.  
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The p38pathway as a possible upstream regulator of SRC-3 
As illustrated in Figure 18, the p38 MAP kinase could be a possible regulator of SRC-3 
through its activation of MK2 (a MAPKAP kinase). The latter is the kinase which directly 
mediates the phosphorylation of SRC-3 at S857. It is evident that further studies are required 




Figure 18: Illustration of pathways investigated in vitro and in vivo for phosphorylation of SRC-3 at S857. MK5 
phosphorylates SRC-3 at S857 efficiently in vitro. Conversely, siRNA mediated knockdown of ERK3 and MK5 failed to 
prove this pathway to be involved in phosphorylation in vivo (red color). ERK2 did not phosphorylate SRC-3 at S857 
efficiently neither in vitro nor in vivo (green color).The p38 MAPK did not phosphorylate SRC-3 at S857 efficiently in vitro, 
but stimulation of p38 with the stress-activator anisomycin increased the phosphorylation more than 2-fold in vivo (blue 
color). By using the p-38 inhibitor SB-202190 (purple), the levels of phosphorylation in vivo decreased. MK2, a downstream 
target of p38, phosphorylate SRC-3 at S857 efficiently in vitro. Taken together, our results indicate the p38 pathway to be 
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In 2004, Wu et al reported the SRC-3 residue S857 to be phosphorylated by the IκB kinase 
(IKK), but not by p38 MAPK (44). They hypothesized that different phosphorylated forms of 
SRC-3 are utilized by distinct signaling pathways to exert distinct physiological responses. 
Their siRNA assays resulted in the identification of S505, S543, S860 and S867, and not 
S857, as residues phosphorylated by the p38 MAP kinase. This is in contrast to our results, 
which suggest that the p38 MAPK signaling pathway can mediate phosphorylation of the 
S857 residue through its downstream effector MK2 or MK3. This association has not been 
reported earlier. In fact, no MAPKAPKs have been suggested to phosphorylate S857 or any 
other site of SRC-3 before.   
The residues S857, S860 and S867 are unique and amongst the SRC-family are found only in 
SRC-3, and they all reside in the CBP-interaction domain (CID) of SRC-3. Interestingly, Wu 
et al tested knockdown of p38 and found it not to affect SRC-3 phosphorylation at S857. 
These experiments should be repeated using various cell lines to further study the association 
of the p38 MAPK and the SRC-3 residue S857.     
The fact that SRC-3 is a transcriptional co-activator for the transcription factor NF-κB, which 
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7 CONCLUSION/FUTURE PERSPECTIVES 
 
Much more work is required to further investigate our findings that the p38 pathway is 
involved in the phosphorylation of SRC-3 at S857 both in vitro and in vivo. This could be 
addressed by using knockout mice that lack the expression of MK2. Elucidation of upstream 
regulators of SRC-3 will increase our understanding of the molecular aspects of SRC-3 
phosphorylation. This will enable us to take advantage of this knowledge in the development 
of novel cancer therapeutics that could hopefully prove to be beneficial for various groups of 
cancer patients. For this reason, our observations could be of clinical importance. 
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APPENDIX 
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5 5 25 X 50 50 10 
10 5 25 X 50 50 10 
20 5 25 X 50 50 10 
40 5 25 X 50 50 10 
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Appendix 2: Phosphorylation of CID SRC-3 at S857 by 5-40 ng MK5 
 








Appendix 3: Phosphorylation of CID SRC-3 at S857 by 100 ng MK5 
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Appendix 4: Phosphorylation of CID SRC-3 at S857 by 5-40 ng MK2 
 








Appendix 5: Phosphorylation of CID SRC-3 at S857 by 100 ng MK2 
 
Time (min) of incubation 
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Appendix 7: SeeBlue® Plus2 Pre-Stained Protein Standard 1x 
Invitrogen, Life Technologies™ (www.lifetechnologies.com) 
 
 
